Back to Search
Start Over
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.
- Source :
-
Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Jun; Vol. 37, pp. 168-175. Date of Electronic Publication: 2024 Apr 10. - Publication Year :
- 2024
-
Abstract
- Objectives: To report trends in carbapenem resistance and difficult-to-treat resistance (DTR) among clinical isolates of Gram-negative priority pathogens collected by the ATLAS global surveillance program from 2018 to 2022.<br />Methods: Reference broth microdilution testing was performed in a central laboratory for 79,214 Enterobacterales, 30,504 Pseudomonas aeruginosa, and 13,500 Acinetobacter baumannii-calcoaceticus complex isolates collected by a constant set of 157 medical centres in 49 countries in Asia Pacific (APAC), Europe (EUR), Latin America (LATAM), Middle East-Africa (MEA), and North America (NA) regions. MICs were interpreted by 2023 CLSI M100 breakpoints. β-lactamase genes were identified for meropenem-nonsusceptible (MIC ≥2 mg/L) Enterobacterales isolates.<br />Results: Carbapenem-resistant Enterobacterales (CRE) detection increased (P < 0.05) in APAC, EUR, LATAM, and MEA regions and decreased in NA, while annual DTR percentages increased in all five regions. Carbapenem-resistant P. aeruginosa (CRPA; decreased in MEA region) and carbapenem-resistant A. baumannii-calcoaceticus complex (CRAB; decreased in MEA region and increased in EUR) remained relatively stable over time in all regions, although notably, annual percentages of CRAB and DTR A. baumannii-calcoaceticus complex isolates were consistently >25 percentage points lower in NA than in other regions. For all regions except NA, the majority of changes in CRE percentages could be attributed to hospital-acquired infections. Among meropenem-nonsusceptible Enterobacterales, KPC was the most frequent carbapenemase in NA and EUR each year. NDM was the most prevalent carbapenemase detected in 2022 in other global regions.<br />Conclusion: CRE, CRPA, CRAB, and DTR rates vary among global regions over time highlighting the need for continuing surveillance to inform treatment strategies and antimicrobial stewardship.<br /> (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Subjects :
- Humans
World Health Organization
Pseudomonas aeruginosa drug effects
Pseudomonas aeruginosa genetics
Pseudomonas aeruginosa isolation & purification
Acinetobacter baumannii drug effects
Acinetobacter baumannii genetics
Acinetobacter baumannii isolation & purification
beta-Lactamases genetics
Global Health
Epidemiological Monitoring
Gram-Negative Bacterial Infections microbiology
Gram-Negative Bacterial Infections epidemiology
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacteria drug effects
Gram-Negative Bacteria isolation & purification
Gram-Negative Bacteria genetics
Gram-Negative Bacteria classification
Enterobacteriaceae drug effects
Enterobacteriaceae genetics
Enterobacteriaceae isolation & purification
Carbapenems pharmacology
Microbial Sensitivity Tests
Anti-Bacterial Agents pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 2213-7173
- Volume :
- 37
- Database :
- MEDLINE
- Journal :
- Journal of global antimicrobial resistance
- Publication Type :
- Academic Journal
- Accession number :
- 38608936
- Full Text :
- https://doi.org/10.1016/j.jgar.2024.03.020